DURECT Corporation (Nasdaq: DRRX) announced today that the results from the recently completed Phase 2a study of DUR-928 in patients with alcoholic hepatitis (AH) have been selected for an oral presentation as part of the late-breaking session of The Liver Meeting® 2019, the annual meeting of the American Association for the Study of Liver Diseases (AASLD), taking place on November 8-12, 2019, in Boston.
October 21, 2019
· 5 min read